GAD2 and type 1 diabetes mellitus: The results from a phase II clinical trial that tested intra-lymphatic GAD65/alum administration along with vitamin D supplementation hold promise that this treatment may slow the loss of residual insulin production after T1D onset in an HLA-restricted subset of new-onset T1D patients [5,6].